Please login to the form below

Not currently logged in
Email:
Password:

Juno Therapeutics

This page shows the latest Juno Therapeutics news and features for those working in and with pharma, biotech and healthcare.

BMS and 2seventy bio move away from CAR-T programme

BMS and 2seventy bio move away from CAR-T programme

This cancellation is the second anti-BCMA CAR-T programme to be halted under BMS in the last twelve months, after a development programme with Juno Therapeutics was scrapped in February

Latest news

  • FDA begins speedy review of BMS’ CAR-T liso-cel FDA begins speedy review of BMS’ CAR-T liso-cel

    The lawsuit argued that Gilead subsidiary Kite Therapeutics infringed on a patent licensed by BMS’ Juno Therapeutics from Sloan Kettering and Memorial Sloan Kettering Cancer Centre for exclusive rights to its ... However, on that front there are a

  • Gilead owes BMS millions after losing Yescarta patent infringement trial Gilead owes BMS millions after losing Yescarta patent infringement trial

    The basis of the lawsuit is that Yescarta, which is marketed by Gilead’s Kite Pharma division, infringed on a patent licensed by BMS’ Juno Therapeutics from Sloan Kettering and the ... Given that Kite independently developed Yescarta and assumed all

  • Celgene boosts IO presence with Immatics deal Celgene boosts IO presence with Immatics deal

    It also  acquired CAR-T specialist Juno therapeutics for $9bn in 2018, giving it rights to lead CAR-T candidate JCAR017 (lisocabtagene maraleucel).

  • The year of the blockbuster The year of the blockbuster

    These include Juno Therapeutics’ CAR T-cell therapy, lisocabtagene maraleucel, for diffuse large B-cell lymphoma, and Alexion’s next-generation Soliris treatment, ravulizumab, for paroxysmal nocturnal haemoglobinuria.

  • Bluebird and Celgene BCMA CAR-T kicks off ASCO Bluebird and Celgene BCMA CAR-T kicks off ASCO

    s lymphoma developed by Juno Therapeutics, which was acquired by Celgene earlier this year. ... That includes data on Jounce Therapeutics’ ICOS-targeting antibody JTX-2011 which disappointed investors when the ASCO abstract was made public earlier this

More from news
Approximately 7 fully matching, plus 19 partially matching documents found.

Latest Intelligence

  • Sourcing R&D innovation: why pharma companies need to evolve their business models Sourcing R&D innovation: why pharma companies need to evolve their business models

    and. CAR-T therapies. Gilead’s acquisition of Kite Pharma and Bristol-Myers Squibb’s acquisition of Juno Therapeutics, as well as the merger and acquisition agreements between Novartis/Spark and

  • The European Medicines Agency: PRIME’d for access? The European Medicines Agency: PRIME’d for access?

    sales, and 6 are in the top 10 companies with Pfizer (with Spark Therapeutics), Novartis (by acquiring AveXis), Celgene (with Bluebird and through acquiring Juno Therapeutics), Sanofi, Roche and Merck all ... Those prices pale in comparison though when

  • Deal Watch January 2018

    Impact Biomedicines for a potential $7bn in early January and then it scooped up the remaining 90% of its CAR-T and TCR technology partner Juno Therapeutics for $9bn. ... Juno Therapeutics/ Celgene. CAR-T and TCR therapeutics portfolio incl JCAR017

  • Deal Watch November 2016 Deal Watch November 2016

    One piece of unwelcome news this month was from Juno Therapeutics, which announced it had halted a phase 2 trial of JCAR015, its CAR T cell immunotherapeutic, in patients with relapsed ... This is despite some positive news for Juno released at the

  • Pharma deals in July 2015 Pharma deals in July 2015

    It still sounds like a high price but perhaps it is in Celgene'sDNA because only a month ago it bought shares in Juno Therapeutics at over a 100% premium in

More from intelligence
Approximately 0 fully matching, plus 8 partially matching documents found.

Latest appointments

  • PureTech Health appoints new chief financial officer PureTech Health appoints new chief financial officer

    Muijrers has worked with pharmaceutical clients such as Kite Pharma, Ablynx and Juno Therapeutics, and said: “I am thrilled to join PureTech Health, one of the most exiciting and unique biopharma

  • Juno Therapeutics names Cindy Elkins as CIO Juno Therapeutics names Cindy Elkins as CIO

    Cindy Elkins has joined Juno Therapeutics - now a part of Celgene - as its new chief information officer, a role that will see her report directly to Hans Bishop, Juno’s president ... She said: “I am delighted to join Juno, a company that reflects my

More from appointments
Approximately 1 fully matching, plus 1 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
dna Communications

Healthcare communications with unique thinking, insight and attitude...

Latest intelligence

Creative awakening2
A creative awakening – how pharma is bringing innovation to the patient journey
By Danny Buckland...
MEDSCAPE EDUCATION: The Human Story in Virtual Patient Simulation
...
Windrush Day
Innnovative Trials' Equality & Diversity committee raises awareness around Windrush Day and the Windrush generation...